Interaction of cyclosporin A with antilymphocyte serum and with enhancing serum for the suppression of renal allograft rejection in the rat

W P HomanP J Morris


The interactions between antilymphocyte serum (ALS) and cyclosporin A and between enhancing serum cyclosporin A were investigated in a DA to Lewis rat renal allograft model. Subtherapeutic doses of cyclosporin A (2 mg/kg/day), when combined with enhancing serum, produced no consistently beneficial effect in animal survival. A short course of cyclosporin A in therapeutic doses (5 mg/kg/day for 4 days) with enhancing serum was also no better than either agent used alone in prolonging rat survival. Subtherapeutic doses of ALS along with subtherapeutic doses of cyclosporin A (2 mg/kg/day) showed a favorable interaction, prolonging animal survival to a median of 59 days. Combination of immunosuppressive agents did not improve the histological picture of allograft rejection when compared to that seen when the agents were used individually. That cyclosporin A plus ALS show a favorable interaction, whereas cyclosporin A plus enhancing serum does not, may indicate that cyclosporin A and enhancing serum operate on the same portion of the immune response.


Jun 1, 1995·Transplant Immunology·R EsmeraldoP J Morris
Feb 1, 1984·The Journal of Surgical Research·J R Nash, P R Bell
Apr 1, 1981·Scottish Medical Journal·A W Thomson, I D Cameron

Related Concepts

Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine)
Dose-Response Relationship, Immunologic
Drug Interactions
Drug Augmentation
Graft Enhancement, Immunologic
Graft Rejection
Immune Sera
Therapeutic Immunosuppression

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.